Cellular and molecular determinants of cisplatin resistance

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1535-1542

  Perez, R P ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Biochemical modulation; Cisplatin; Drug accumulation; Drug resistance; Glutathione; High mobility group (HMG) proteins; Metallothionein; Mismatch repair; Nucleotide excision repair

Indexed keywords

3 AMINOBENZAMIDE; ANTINEOPLASTIC AGENT; APHIDICOLIN; CALMODULIN INHIBITOR; CARBOPLATIN; CISPLATIN; CYTARABINE; DIPYRIDAMOLE; DNA TOPOISOMERASE INHIBITOR; FLUDARABINE; GEMCITABINE; GLUTATHIONE; HYDROXYUREA; IFOSFAMIDE; METALLOTHIONEIN; NALIDIXIC ACID; NOVOBIOCIN; PLATINUM DERIVATIVE; ZIDOVUDINE;

CANCER CHEMOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG DNA BINDING; DRUG SENSITIVITY; EXCISION REPAIR; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0032169105     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00227-5     Document Type: Article

References (108)

1. 1. Ozols RF, Williams SD. Testicular cancer. Curr Prob Cancer 1989, 13, 287-335.
2. 2. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984, 100, 704-713.
3. 3. Ozols RF. Ovarian cancer, part II: treatment. Curr Prob Cancer 1992, 16, 63-126.
4. 4. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993, 67, 1171-1176.
5. 5. Douple EB. Cis-diamminedichloroplatinum(II): effects of a representative metal coordination complex on mammalian cells. Pharmac Ther 1984, 25, 297-326.
6. 6. Eastman A. Re-evaluation of the interaction of cis-dichloro (ethylenediamine)platinum(II) with DNA. Biochemistry 1986, 25, 3912-3915.
7. 7. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro (ethylenediamine)platinum(II). Biochemistry 1983, 22, 3927-3933.
8. 8. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986, 46, 1972-1979.
9. 9. Fraval H, Rawlings C, Roberts J. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymidine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res 1978, 51, 121-132.
10. 10. Hoy C, Thompson L, Mooney C, Salazar E. Defective DNA crosslink removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res 1985, 45, 1737-1743.
11. 11. Dijt F, Fitchinger-Schepman A, Berends F, Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988, 48, 6058-6062.
12. 12. Masuda H, Ozols RF, Lai G-M, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988, 48, 5713-5716.
13. 13. Lai G-M, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988, 37, 4597-4600.
14. 14. Masuda M, Tanaka T, Matsuda H, Kusaba I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 1990, 50, 1863-1866.
15. 15. Parker RJ, Eastman A, Bostick-Burton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991, 87, 772-777.
16. 16. Johnson SW, Perez RP, Godwin AK, et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 1994, 47, 689-697.
17. 17. Katz E, Andrews P, Howell S. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Communicat 1990, 2, 159-164.
18. 18. Searle J, Kerr JFR, Bishop CL. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu 1982, 17, 229-259.
19. 19. Searle J, Lawson TA, Harmon AB, Kerr JFR. An electron microscope study of the mode of cell death induced by cancer chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 1975, 116, 129-138.
20. 20. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980, 68, 251-307.
21. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990, 82, 749-755.
22. 22. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins, and hyperthermia. Biochem Pharmacol 1990, 40, 2353-2362.
23. 23. Evans DE, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993, 53, 2133-2139.
24. 24. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990, 2, 275-280.
25. 25. Bollenbacher J, Glaves D, Pendyala L, Perez R. Altered mRNA expression of P53 and BAX in a cisplatin-resistant human ovarian carcinoma cell line. Proc Amer Assoc Cancer Res 1997, 38, 136.
26. 26. Russell PJ, Glaves D. Experimental models of bladder cancer. In Raghavan D, Scher HI, Leibel SA, Lange PH, eds. Principles and Practice of Genitourinary Oncology. Philadelphia, Lippincott-Raven, 1997, 195-206.
27. 27. Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Gynecol Oncol 1995, 85, 1007-1010.
28. 28. Chu G. Cellular responses to cisplatin: the roles of DNA binding proteins and DNA repair. J Biol Chem 1994, 269, 787-790.
29. 29. Karran P, Bignami M. DNA damage tolerance, mismatch repair, and genome instability. BioEssays 1994, 16, 833-839.
30. 30. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995, 5, 382-395.
31. 31. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271, 19645-19648.
32. 32. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56, 3087-3090.
33. 33. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis, and loss of P53 function in drug-resistant tumor cells. Cancer Res 1996, 56, 1374-1381.
34. 34. Fink D, Nebel Aebi S, Zheng H, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56, 4881-4886.
35. 35. Ferry KV, Fink D, Johnson SW, Hamilton TC, Howell SB. Quantitation of platinum-DNA adduct repair in mismatch repair deficient and proficient human colorectal cancer cell lines using an in vitro DNA repair assay. Proc Am Assoc Cancer Res 1997, 38 (abstract), 359.
36. 36. Fink D, Nebel S, Aebi S, Nehme A, Howell SB. Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Int J Oncol 1997, 11, 539-542.
37. 37. Yamada M, O'Regan E, Brown R, Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucl Acids Res 1997, 25, 491-495.
38. 38. Duckett DR, Drummond JT, Murchie AIH, et al. Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylmine, or the cisplatin-d (GpG) adduct. Proc Natl Acad Sci 1996, 93, 6443-6447.
39. 39. Wunderlich V, Bottger M. High-mobility-group proteins and cancer - an emerging link. J Cancer Res Clin Oncol 1997, 123, 133-140.
40. 40. Hughes EN, Engelsberg BN, Billings PC. Purification of nuclear proteins that bind to cisplatin-damaged DNA: identity with high mobility group proteins 1 and 2. J Biol Chem 1992, 267, 13520-13527.
41. 41. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
42. 42. Treiber DK, Zhai X, Jantzen H-M, Essigmann JM. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci 1994, 91, 5672-5676.
43. 43. Hoffman J-S, Locker D, Villani G, Leng M. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts. J Mol Biol 1997, 270, 539-543.
44. 44. Brown SJ, Kellet PJ, Lippard SJ. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 1993, 261, 603-605.
45. 45. Lambert JR, Bilanchone VW, Cumsky MG. The ORD1 gene encodes a transcription factor involved in oxygen regulation and is identical to IXR1, a gene that confers cisplatin sensitivity to Saccharomyces cerevisiae. Proc Natl Acad Sci 1994, 91, 7345-7349.
46. 46. Andrews P, Howell S. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990, 2, 35-43.
47. 47. Perez R, Hamilton T, Ozols R. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 1990, 48, 19-27.
48. 48. Perez RP, Johnson SW, Hamilton TC. New strategies of systemic therapy: mechanisms and modulation of resistance to platinum-containing anticancer drugs. In Raghavan D, Scher H, Liebel S, Lange P, eds. Principles and Practice of Genitourinary Oncology. Philadelphia, Lippincott-Raven, 1997, 111-119.
49. 49. Fujii R, Mutoh M, Niwa K, et al. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 1994, 85, 426-433.
50. 50. Dedon PC, Borch RF. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 1987, 36, 1955-1964.
51. 51. Mistry P, Loh SY, Kelland LR. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int J Cancer 1993, 55, 849-856.
52. 52. Eastman A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 1987, 61, 241-248.
53. 53. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of glutathioneplatinum complex and its biological significance. J Biol Chem 1993, 268, 20116-20125.
54. 54. Pattanaik A, Bachowski G, Laib J. Properties of the reaction of cis-dichlorodiammineplatinum (II) with metallothionein. J Biol Chem 1992, 267, 16121-16128.
55. 55. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988, 241, 1813-1815.
56. 56. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987, 19, 149-154.
57. 57. Schilder RJ, Hall L, Monks A. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990, 45, 416-422.
58. 58. Ahn H, Lee E, Kim K, Lee C. Effect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines. J Urol 1994, 151, 263-267.
59. 59. Pendyala L, Velagapudi S, Toth K, et al. Translational studies of glutathione in bladder cancer. Clin Cancer Res 1997, 3, 793-798.
60. 60. Behrens BC, Hamilton TC, Masuda H. Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987, 47, 414-418.
61. 61. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian cancer cell lines. Br J Cancer 1991, 64, 215-220.
62. 62. Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Nat Acad Sci USA 1992, 89, 3070-3074.
63. 63. Britten RA, Green JA, Warenius HM. Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiation Oncology Biol Phys 1992, 24, 527-331.
64. 64. Teicher BA, Holden SA, Kelley MJ. Characterization of a human squamous-carcinoma cell line resistant to cisp-diamminedichloroplatinum (II). Cancer Res 1987, 47, 388-393.
65. 65. Andrews PA, Murphy MP, Howell SB. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian-carcinoma cells by glutathione depletion. Cancer Res 1985, 45, 6250-6253.
66. 66. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res 1987, 47, 2056-2061.
67. 67. Bohr VA. Gene specific DNA repair. Carcinogenesis 1991, 87, 1983-1992.
68. 68. Zhen W, Link CJJ, O'Connor PM, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992, 12, 3689-3698.
69. 69. Johnson SW, Swiggard PA, Handel LM, et al. Relationship between platinum-DNA adduct formation, removal, and cytotoxicity in cisplatin sensitive and resistant human ovarian cancer cells. Cancer Res 1994, 54, 5911-3916.
70. 70. Hill BT, Shellard SA, Hosking LK, Fitchinger-Shepman AMJ. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diamminedichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int J Radiat Oncol Biol Phys 1990, 19, 75-83.
71. 71. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian carcinoma cell lines. Cancer Res 1997, 57, 850-856.
72. 72. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian cancer cell lines. Cancer Res 1994, 54, 3500-3505.
73. 73. Vaisman A, Varchenko M, Chaney SG. Correlation between mismatch repair and increased replicative bypass in cisplatin resistant cell lines. Proc Am Assoc Cancer Res 1997, 38 (abstract), 312.
74. 74. Kastan MB, Onyekwere O, Sidrasky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51, 6304-6311.
75. 75. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993, 8, 307-318.
76. 76. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci 1992, 89, 7491-7495.
77. 77. El-Diery W, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817-825.
78. 78. Kawasaki T, Tomita T, Bilim V, Takeda M, Takahashi K, Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder cancer cell lines with p21/ WAF1/CIP1 and/or P53 gene alterations. Int J Cancer 1996, 68, 501-505.
79. 79. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997, 14, 9229-9935.
80. 80. Gallagher WM, Cairney M, Schott B, Roninson IB, Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 1997, 14, 185-193.
81. 81. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74, 609-619.
82. 82. Reed X. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994, 124, 1-6.
83. 83. Fisher D. Apoptosis in cancer therapy: crossing the threshold. Cell 1994, 78, 539-542.
84. 84. Miyashita T, Reed X. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293-299.
85. 85. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9, 1799-1805.
86. 86. Selvakumaran M, Lin H-K, Miyashita T, et al. Immediate upregulation of bax expression by p53 but not TFGβ1: a paradigm for distinct apoptotic pathways. Oncogene 1994. 9, 1791-1798.
87. 87. Zhan Q, Fan S, Bae I, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994, 9, 3743-3751.
88. 88. Perego P, Giola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 Rene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56, 556-562.
89. 89. Fajac A, DaSilva J, Ahomadegbe J-C, et al. Cisplatin-induced apoptosis and P53 gene status in a cisplatin-resistance human ovarian carcinoma cell line. Int J Cancer 1996, 68, 67-74.
90. 90. Dole M, Nunez G, Merchant AK, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994, 54, 3253-3259.
91. 91. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81, 151-157.
92. 92. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of P53 and Bel-2. Oncogene 1995, 11, 1217-1228.
93. 93. Tokino T, Thaagalingam S, El-Deiry W, Waldman T, Kinzler KW, Vogelstein B. p53 tagged sites from human genomic DNA. Hum Mol Genet 1994, 3, 1537-1542.
94. 94. Perez R, Johnson S, Handel L, O'Dwyer P, Hamilton T. Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells. Gynecol Oncol 1995, 58, 312-318.
95. 95. Lai G-M, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Biochem Pharmacol 1989, 37, 4597-4600.
96. 96. Billings PC, Davis RJ, Engelsberg BN, Skov KA, Hughes EN. Characterization of high mobility group protein binding to cisplatin-damaged DNA. Biochem Biophys Res Comm 1992, 188, 1286-1294.
97. 97. Bergelson S, Pinkus R, Daniel V. Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione s-transferase gene expression. Cancer Res 1994, 54, 36-40.
98. 98. Potapova O, Haghighi A, Bost F, et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997, 272, 14041-14044.
99. 99. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270, 1326-1331.
100. 100. Chen G, Zeller W. Augmentation of cisplatin (DDP) cytotoxicity in vivo by D,1-buthionine sulfoximine (BSO) in DDP-sensitive and -resistant rat ovarian tumors and its relation to DNA interstrand crosslinks. Anticancer Res 1991, 11, 2231-2238.
101. 101. O'Dwyer P, Hamilton T, Young R, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 1992, 84, 264-267.
102. 102. Bailey HH, Mulcahy RT, Tutsch KD, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994, 12, 194-205.
103. 103. Bailey HH, Wilding G, Tutsch KD, et al. A phase I trial of L-S,R-buthionine sulfoximine (BSO) given as a 24-to 48-hour continuous infusion (CI) with iv melphalan (L-PAM). Proc Amer Soc Clin Oncol 1994, 13 (abstract), 334-330.
104. 104. Yao K-S, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ. Variable baseline γ-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 1993, 53, 3662-3666.
105. 105. Pendyala L, Creaven PJ, Raghavan D, et al. Thiols in patients (pts) receiving ifosfamide (IF) with mesna and carboplatin (CB). Proc Am Assoc Cancer Res 1997, 38 (abstract), 390.
106. 106. Lind L, McGown A, Hadfield J, Thatcher N, Crowther D, Fox B. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochemical Pharmacol 1989, 38, 1835-1840.
107. 107. Meier T, Allenbacher A, Mueller E, et al. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anti-cancer Drugs 1994, 5, 403-409.
108. 108. Malik IA, Mehboobali N, Iqbal MP. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 1997, 39, 561-565.